Mei‐Sze Chua

A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways

This paper develops a niclosamide sulfate prodrug, SSL-0024, which improves solubility and bioavailability, showing strong anti-tumor effects against hepatocellular carcinoma through multiple pathway inhibition.

Niclosamide Prodrug Enhances Oral Bioavailability and Targets Vasorin-TGFβ Signaling in Hepatocellular Carcinoma

This study develops a niclosamide prodrug (NIC-PS) with improved bioavailability and shows it targets VASN-TGFβ signaling to reduce HCC tumor volume and enhance therapeutic responses.

Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19

Rapid Identification and Validation of Novel Rheumatoid Arthritis Drug Treatments using an Integrative Bioinformatics Platform

The paper identifies and validates three novel drug candidates for rheumatoid arthritis using a computational model integrated with in vivo testing.

5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages

The paper analyzes 5-hydroxymethylcytosine in cell-free DNA to predict tumor types and stages with high accuracy.